Login to Your Account



Clinic Roundup


Wednesday, September 12, 2012

• InSite Vision Inc., of Alameda, Calif., completed patient enrollment in the Phase III DOUBle (Dual Ophthalmic agents Used in Blepharitis) trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) in blepharitis. The study enrolled more than 900 patients with moderate to severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription